Welcome to the CI Agent Dashboard
Monitor competitive intelligence across multiple pharmaceutical companies. Use the client selector to switch between companies or enable cross-client comparison mode.
Data Source Integration Status
12 new trials added today
3 status updates processed
8 new publications indexed
2 high-impact papers identified
1 new approval announced
2 advisory committee meetings scheduled
Merck Pharmaceuticals
Enterprise Plan • Last updated: June 9, 2025
24
Total Alerts
8
Pipeline Updates
12
Clinical Trial Changes
4
Regulatory Updates
Pfizer Inc.
Enterprise Plan • Last updated: June 9, 2025
31
Total Alerts
14
Pipeline Updates
9
Clinical Trial Changes
8
Regulatory Updates
Novartis AG
Enterprise Plan • Last updated: June 9, 2025
19
Total Alerts
6
Pipeline Updates
10
Clinical Trial Changes
3
Regulatory Updates
Johnson & Johnson
Enterprise Plan • Last updated: June 9, 2025
27
Total Alerts
11
Pipeline Updates
8
Clinical Trial Changes
8
Regulatory Updates
Recent Activity
Phase 3 trial for MK-7189 in NSCLC has completed enrollment
FDA approves supplemental NDA for LORBRENA in first-line ALK+ NSCLC
New NEJM publication on Kesimpta long-term safety data in multiple sclerosis
Predictive Analytics AI
View All PredictionsMK-7189 Phase 3 trial likely to report positive results in Q3 2025 based on interim data patterns and similar trial outcomes
PF-06939926 likely to face FDA advisory committee meeting challenges based on safety signals in similar gene therapies
PACIFIC-2 trial enrollment likely to complete 2-3 months ahead of schedule based on current recruitment patterns
Latest Data Snacks AI
View All Data SnacksTrial Milestone Tracker
Generated today5 major Phase 3 readouts expected in Oncology this quarter, with Merck's MK-7189 and BMS's relatlimab combination as key ones to watch.
Regulatory Radar
Generated todayFDA PDUFA dates clustering in Q3 2025 for immunology assets, with 3 JAK inhibitors and 2 IL-23 inhibitors awaiting decisions.
Shifting MOA Trends
Generated todayBispecific antibodies gaining momentum in oncology pipeline with 24% YoY growth in clinical trials, primarily in hematologic malignancies.